Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Helyx Industries S.p.A. is an Italian-based healthcare biotechnology company focused on the development, production, and commercialization of in-vitro diagnostic medical devices within Italy. Central to its offerings is the Sagitta platform, which delivers an array of diagnostic assays such as Ladymed/HPV Selfy for human papillomavirus (HPV) screening, CoronaMelt for SARS-CoV-2 identification, CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants, and UlisseFaster, a reagent used for biological sample pre-treatment. Beyond this, the firm provides various tests and reagents tailored for sexually transmitted diseases and HPV. Further expanding its capabilities, Helyx utilizes its NanoHybrid platform to detect specific antibodies and protein analytes directly from whole blood or serum, and the Aptavir platform, dedicated to creating and manufacturing synthetic nucleic acid molecules aimed at curbing pathogen infectivity. Founded in Udine, Italy, in 2015 as Ulisse Biomed S.p.A., the company will officially adopt its current name, Helyx Industries S.p.A., in December 2025.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of UBM.MI is 1.4 and suggests 71% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre